Day: September 21, 2022

Please see the article here for a Q+A interview with Dunad CEO Pearl Huang in Nature Reviews Drug Discovery.

NT-0796 successfully completes Phase 1 study, demonstrating blood-brain barrier penetration and reduced inflammatory biomarkers supporting advancement in neuroinflammatory   and peripheral inflammatory diseases Second clinical candidate